Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Bryn Mawr’s CIO on Liquidity and Navigating Market Turbulence James Comtois Judy Chambers, Managing Director, Meketa Investment Group Institutional Investor C-PACE: The Rapidly Growing Corner of Real Estate Finance Catching Institutional Attention Sponsored by Nuveen